TABLE IV.

Baseline predictors of clinical asthma remission in female subjects^*†

Clinical phenotype	OR	95% CI	P value
Hispanic race	9.84	2.60–39.39	<.001
Moderate airway hyperresponsiveness (PC20 1–4 mg/mL)‡	0.37	0.15–0.89	.03
Severe airway hyperresponsiveness (PC20 <1 mg/mL)‡	0.24	0.09–0.64	.005
FEV1/FVC ≥90%§	54.76	7.56–1166.80	<.001
FEV1/FVC 80% to 89%§	12.13	2.00–239.14	.02
FEV1/FVC 70% to 79%§	1.44	0.20–29.90	.75

^*Covariates included in the cross-validated model: age, CAMP treatment group, clinic site, household income level, history of wheezing with colds, history of exacerbations after exercise, history of exposure to home tobacco smoke, and serum IgE level.

^†Quantitative variables were modeled categorically.

^‡Reference level is a PC₂₀ of greater than 4 mg/mL.

^§Reference level is an FEV₁/FVC ratio of less than 70%.